Here’s another disturbing health trend caused in part by this country’s obesity epidemic: Nonalcoholic Fatty Liver Disease (NAFLD) – which is a strong independent risk factor for cardiovascular death – is now the most prevalent liver disease in America. While there is no established treatment, university researchers are excited by promising results using tocotrienols (Vitamin E) from palm fruit oil. Palm fruit oil is the richest source of tocotrienols, yielding a Vitamin E complex that is very high in antioxidants.
What is NAFLD?
NAFLD results from the accumulation of excess fats (triglycerides) in the liver of people who drink little-to-no alcohol. It is usually associated with obesity, insulin resistance and high cholesterol (metabolic syndrome), and is now the most common cause (24 percent) of abnormal liver function among U.S. adults. The U.S. is not the only country dealing with this upsurge. NAFLD is thought to affect 15-30 percent of the general adult populations in Western countries, 21 percent in Shanghai, between 18 and 30 percent in Japan and about 14 percent in Thailand.
NAFLD is difficult to detect because most people show no signs or complications, but some experts estimate that 90 percent of people who are obese and those who have been diagnosed with type 2 diabetes may also have this fatty liver disease.
There is currently no drug that can effectively cure or treat NAFLD.
Vitamin E from Palm Fruit Oil shows tremendous potential as an antidote
Researchers at University Science Malaysia’s School of Pharmaceutical Sciences in Malaysia have now confirmed that Vitamin E tocotrienols from palm fruit oil hold promise for the millions of people suffering from NAFLD.
During the one-year double-blind, placebo-controlled clinical trial, researchers gave 200 mgs of Vitamin E tocotrienols (as Tocomin SupraBio) twice daily, or a placebo, to 64 adults suffering from NAFLD. At the end of the trial, 20 out of the 30 volunteers (66.7 percent) treated with the Vitamin E tocotrienols showed improvements, with 15 (50 percent) showing no signs of the disease. Only 23.3 percent (7 out of 30) of the control group became NAFLD negative.
These research results were presented at the Liver Meeting of the American Association for the Study of Liver Diseases (ASSLD), Boston in October, 2010. The abstract has also been accepted and published in the Official Journal of AASLD.